Investment

London-headquartered venture capital firm Atomico has announced its largest ever fundraise, totalling £1 billion.

The VC’s two new funds will support Europe’s most ambitious founders.

The new $754m Atomico Growth VI partners with entrepreneurs from Series B to pre-IPO. It sits alongside a $485m early stage fund, Atomico Venture VI, which continues our commitment to working with founders earlier in their journey, predominantly at Series A, alongside occasional Seed opportunities.

Niklas Zennström, founder and CEO of Atomico, said: “European technology is coming of age. Meeting this opportunity requires ambition, hustle and commitment from founders, who need investors with the experience and perspective to see beyond market cycles.

“Data shows Europe is leading the world at the early stage with a wealth of new start-ups. Our new funds bring them essential fire power to level up and achieve global scale – from Europe.”

Europe now captures close to 30 per cent of global early stage funding and is creating more new companies than any other region.

Data shows Europe is leading the world at the early stage with a wealth of new startups.

Atomico backs Ben in £13m Series A round

Atomico say their new funds will provide ‘essential fire power to level up and achieve global scale’.

The company describes itself as a ‘generalist technology investor’ and takes a founder-focussed approach to help European entrepreneurs succeed.

Atomico  has already made 21 investments from the new funds. Atomico Growth VI has most recently partnered with Cologne’s Deepl; Copenhagen’s Corti;  and London-born virtual clinic provider Pelago.

Atomico Venture VI investments include Stockholm’s Neko Health; London’s Ben and Dexory; Berlin’s Deeploi; Oslo’s Strise; and Zurich’s Lakera.

Andreas Cleve, co-founder and CEO of Corti, said: “When we chose to partner with Atomico, our motivation was more than just funding; it was about finding a collaborator who truly understands what it will take to build the world’s most trusted generative AI for healthcare.

“Atomico has been a partner in every sense, diving straight into the trenches to navigate the complexities of scaling responsibly and effectively.”

Since Atomico was founded in 2006, the VC has made over 155 investments across 15 European countries. One in six of Atomico’s portfolio is currently valued in excess of $1bn.

£35m funding injection for AI drug discovery firm